Pacira

News

Viatris builds in pain relief with $1.65bn Pacira purchase

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira BioSciences.

News

Close-up image of a firm handshake between two colleagues

Supernus bulks up its Parkinson's portfolio with Adamas take...

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stabl

News

Illustration of a nerve cell on a colored background with light effects

Pacira CEO hopes for further expansion to US nerve block lab...

CEO wants "broad nerve block label" for Exparel

News

FDA advisers reject new use for Pacira nerve block

Doubts over nerve blocker Exparel

Viatris builds in pain relief with $1.65bn Pacira purchase

Supernus bulks up its Parkinson's portfolio with Adamas take...

Pacira CEO hopes for further expansion to US nerve block lab...

FDA advisers reject new use for Pacira nerve block

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Pacira

Editor's Picks